CeriBell, Inc.
CBLL Healthcare Medical Devices
CeriBell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $89.1 million, up 36.1% from fiscal 2024. In the quarter to June 2026, revenue grew 32.5%, EPS fell 34.2%, free cash flow fell 68.6% and total debt rose 1.52%, each against the same quarter a year earlier.
Follow CBLL
CeriBell, Inc. (CBLL) Piotroski F-score
CeriBell, Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (25.36%) | (28.46%) | Fail | 0 |
| Positive operating cash flow | (40.81m) | (35.04m) | Fail | 0 |
| Rising return on assets | (25.36%) | (28.46%) | Pass | 1 |
| Cash flow above net income | 12.60m | 5.41m | Pass | 1 |
| Falling long-term leverage | 0.09 | 0.14 | Pass | 1 |
| Rising current ratio | 9.73 | 16.73 | Fail | 0 |
| No new shares issued | 36,542,100 | 11,950,000 | Fail | 0 |
| Rising gross margin | 87.89% | 86.72% | Pass | 1 |
| Rising asset turnover | 0.42 | 0.46 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| BVS Bioventus Inc. compare | 8 |
| AORT Artivion, Inc. compare | 7 |
| IRMD iRadimed Corporation compare | 6 |
| IART Integra LifeSciences Holdings Corporation compare | 5 |
| PRCT PROCEPT BioRobotics Corporation compare | 5 |
| ENOV Enovis Corporation compare | 4 |
| CBLL CeriBell, Inc. | 4 |
| TNDM Tandem Diabetes Care, Inc. compare | 3 |
| LMRI Lumexa Imaging Holdings, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover